Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity

Autores
Pereyra, Laura Lucia; Bannoud, Nadia; Guarniolo, D.; Chapana, Agostina Lucía; Sosa Escudero, Miguel Angel; Carvelli, Flavia Lorena
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Breast cancer is one of the most important causes of morbidity and mortality worldwide. It has been shown that the cells of some tumors have an increased lysosomal biogenesis in response to metabolic alterations, which also has an impact on the integrity and/or lysosomal functionality, showing increased levels of lysosomal proteases, such as cathepsin D (CatD). It has been demonstrated that this enzyme induces apoptosis when is released into the cytoplasm. Since the lysosomes could play a role either as initiators or executors of apoptotic processes when the membrane integrity is altered, this organelle could be taken as a potential therapeutic target against tumors. In breast cancer cell lines positive to estrogen receptor RE (REα), CatD is positively regulated by this hormone, while in cell lines negative for REα the enzyme is constitutively overexpressed. Tamoxifen (TAM) is one of the most common anti-estrogenic drugs used in breast cancer therapy. It interacts with ER and inhibits transcriptional activity in the mammary gland. The aim of this study was to evaluate the effect of estrogens and tamoxifen on lysosomal acidification and CatD processing in breast cancer cells. Mammary cell lines MCF-7 (tumorigenic expressing REα), MDA-MB231 (tumorigenic non-expressing REα) and MCF-10A (non-tumorigenic) were treated in the presence or absence of 17-β-estradiol and/or TAM. For quantification of acidic lysosomes, cells were treated with Lysotracker. Cultures were subjected to immunoblot analysis and fluorescence microscopy. As expected, TAM blocked the effect of estrogen on CatD processing in MCF-7 cells. However, TAM used alone, also altered CatD processing and decreased the number of acidic lysosomes in both cell lines. Neither effect of TAM was observed on MCF-10A cell line. In addition, a decreased level of another lysosomal protein, GM2AP (related to the development of tumors), was observed in the cells due to TAM. All these results suggest that TAM has additional effects independent of its anti-estrogenic activity, possibly due to lysosomotropic action.
Fil: Pereyra, Laura Lucia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Ministerio de Salud. Instituto Nacional del Cáncer; Argentina
Fil: Bannoud, Nadia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Guarniolo, D.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Chapana, Agostina Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Sosa Escudero, Miguel Angel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Carvelli, Flavia Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; Argentina
XXXVI Reunión Científica Anual de la Sociedad de Biología de Cuyo
Mendoza
Argentina
Sociedad de Biología de Cuyo
Materia
CATHEPSIN D
BREAST CANCER
ESTROGEN RECEPTOR
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/221665
Acceder
id CONICETDig_a8cfdbc506981e23371708b48d98befe
oai_identifier_str oai:ri.conicet.gov.ar:11336/221665
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activityPereyra, Laura LuciaBannoud, NadiaGuarniolo, D.Chapana, Agostina LucíaSosa Escudero, Miguel AngelCarvelli, Flavia LorenaCATHEPSIN DBREAST CANCERESTROGEN RECEPTORhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Breast cancer is one of the most important causes of morbidity and mortality worldwide. It has been shown that the cells of some tumors have an increased lysosomal biogenesis in response to metabolic alterations, which also has an impact on the integrity and/or lysosomal functionality, showing increased levels of lysosomal proteases, such as cathepsin D (CatD). It has been demonstrated that this enzyme induces apoptosis when is released into the cytoplasm. Since the lysosomes could play a role either as initiators or executors of apoptotic processes when the membrane integrity is altered, this organelle could be taken as a potential therapeutic target against tumors. In breast cancer cell lines positive to estrogen receptor RE (REα), CatD is positively regulated by this hormone, while in cell lines negative for REα the enzyme is constitutively overexpressed. Tamoxifen (TAM) is one of the most common anti-estrogenic drugs used in breast cancer therapy. It interacts with ER and inhibits transcriptional activity in the mammary gland. The aim of this study was to evaluate the effect of estrogens and tamoxifen on lysosomal acidification and CatD processing in breast cancer cells. Mammary cell lines MCF-7 (tumorigenic expressing REα), MDA-MB231 (tumorigenic non-expressing REα) and MCF-10A (non-tumorigenic) were treated in the presence or absence of 17-β-estradiol and/or TAM. For quantification of acidic lysosomes, cells were treated with Lysotracker. Cultures were subjected to immunoblot analysis and fluorescence microscopy. As expected, TAM blocked the effect of estrogen on CatD processing in MCF-7 cells. However, TAM used alone, also altered CatD processing and decreased the number of acidic lysosomes in both cell lines. Neither effect of TAM was observed on MCF-10A cell line. In addition, a decreased level of another lysosomal protein, GM2AP (related to the development of tumors), was observed in the cells due to TAM. All these results suggest that TAM has additional effects independent of its anti-estrogenic activity, possibly due to lysosomotropic action.Fil: Pereyra, Laura Lucia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Ministerio de Salud. Instituto Nacional del Cáncer; ArgentinaFil: Bannoud, Nadia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; ArgentinaFil: Guarniolo, D.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; ArgentinaFil: Chapana, Agostina Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; ArgentinaFil: Sosa Escudero, Miguel Angel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Carvelli, Flavia Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; ArgentinaXXXVI Reunión Científica Anual de la Sociedad de Biología de CuyoMendozaArgentinaSociedad de Biología de CuyoTech Science Press2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/221665Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity; XXXVI Reunión Científica Anual de la Sociedad de Biología de Cuyo; Mendoza; Argentina; 2018; 48-490327-95451667-5746CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://sbcuyo.org.ar/wp-content/uploads/2019/08/Biocell-2018.pdfInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:05:13Zoai:ri.conicet.gov.ar:11336/221665instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:05:13.824CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
title Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
spellingShingle Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
Pereyra, Laura Lucia
CATHEPSIN D
BREAST CANCER
ESTROGEN RECEPTOR
title_short Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
title_full Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
title_fullStr Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
title_full_unstemmed Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
title_sort Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity
dc.creator.none.fl_str_mv Pereyra, Laura Lucia
Bannoud, Nadia
Guarniolo, D.
Chapana, Agostina Lucía
Sosa Escudero, Miguel Angel
Carvelli, Flavia Lorena
author Pereyra, Laura Lucia
author_facet Pereyra, Laura Lucia
Bannoud, Nadia
Guarniolo, D.
Chapana, Agostina Lucía
Sosa Escudero, Miguel Angel
Carvelli, Flavia Lorena
author_role author
author2 Bannoud, Nadia
Guarniolo, D.
Chapana, Agostina Lucía
Sosa Escudero, Miguel Angel
Carvelli, Flavia Lorena
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv CATHEPSIN D
BREAST CANCER
ESTROGEN RECEPTOR
topic CATHEPSIN D
BREAST CANCER
ESTROGEN RECEPTOR
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Breast cancer is one of the most important causes of morbidity and mortality worldwide. It has been shown that the cells of some tumors have an increased lysosomal biogenesis in response to metabolic alterations, which also has an impact on the integrity and/or lysosomal functionality, showing increased levels of lysosomal proteases, such as cathepsin D (CatD). It has been demonstrated that this enzyme induces apoptosis when is released into the cytoplasm. Since the lysosomes could play a role either as initiators or executors of apoptotic processes when the membrane integrity is altered, this organelle could be taken as a potential therapeutic target against tumors. In breast cancer cell lines positive to estrogen receptor RE (REα), CatD is positively regulated by this hormone, while in cell lines negative for REα the enzyme is constitutively overexpressed. Tamoxifen (TAM) is one of the most common anti-estrogenic drugs used in breast cancer therapy. It interacts with ER and inhibits transcriptional activity in the mammary gland. The aim of this study was to evaluate the effect of estrogens and tamoxifen on lysosomal acidification and CatD processing in breast cancer cells. Mammary cell lines MCF-7 (tumorigenic expressing REα), MDA-MB231 (tumorigenic non-expressing REα) and MCF-10A (non-tumorigenic) were treated in the presence or absence of 17-β-estradiol and/or TAM. For quantification of acidic lysosomes, cells were treated with Lysotracker. Cultures were subjected to immunoblot analysis and fluorescence microscopy. As expected, TAM blocked the effect of estrogen on CatD processing in MCF-7 cells. However, TAM used alone, also altered CatD processing and decreased the number of acidic lysosomes in both cell lines. Neither effect of TAM was observed on MCF-10A cell line. In addition, a decreased level of another lysosomal protein, GM2AP (related to the development of tumors), was observed in the cells due to TAM. All these results suggest that TAM has additional effects independent of its anti-estrogenic activity, possibly due to lysosomotropic action.
Fil: Pereyra, Laura Lucia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Ministerio de Salud. Instituto Nacional del Cáncer; Argentina
Fil: Bannoud, Nadia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Guarniolo, D.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Chapana, Agostina Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina
Fil: Sosa Escudero, Miguel Angel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Carvelli, Flavia Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Instituto de Histología y Embriología de Mendoza Dr. Mario H. Burgos; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Exactas y Naturales; Argentina
XXXVI Reunión Científica Anual de la Sociedad de Biología de Cuyo
Mendoza
Argentina
Sociedad de Biología de Cuyo
description Breast cancer is one of the most important causes of morbidity and mortality worldwide. It has been shown that the cells of some tumors have an increased lysosomal biogenesis in response to metabolic alterations, which also has an impact on the integrity and/or lysosomal functionality, showing increased levels of lysosomal proteases, such as cathepsin D (CatD). It has been demonstrated that this enzyme induces apoptosis when is released into the cytoplasm. Since the lysosomes could play a role either as initiators or executors of apoptotic processes when the membrane integrity is altered, this organelle could be taken as a potential therapeutic target against tumors. In breast cancer cell lines positive to estrogen receptor RE (REα), CatD is positively regulated by this hormone, while in cell lines negative for REα the enzyme is constitutively overexpressed. Tamoxifen (TAM) is one of the most common anti-estrogenic drugs used in breast cancer therapy. It interacts with ER and inhibits transcriptional activity in the mammary gland. The aim of this study was to evaluate the effect of estrogens and tamoxifen on lysosomal acidification and CatD processing in breast cancer cells. Mammary cell lines MCF-7 (tumorigenic expressing REα), MDA-MB231 (tumorigenic non-expressing REα) and MCF-10A (non-tumorigenic) were treated in the presence or absence of 17-β-estradiol and/or TAM. For quantification of acidic lysosomes, cells were treated with Lysotracker. Cultures were subjected to immunoblot analysis and fluorescence microscopy. As expected, TAM blocked the effect of estrogen on CatD processing in MCF-7 cells. However, TAM used alone, also altered CatD processing and decreased the number of acidic lysosomes in both cell lines. Neither effect of TAM was observed on MCF-10A cell line. In addition, a decreased level of another lysosomal protein, GM2AP (related to the development of tumors), was observed in the cells due to TAM. All these results suggest that TAM has additional effects independent of its anti-estrogenic activity, possibly due to lysosomotropic action.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/221665
Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity; XXXVI Reunión Científica Anual de la Sociedad de Biología de Cuyo; Mendoza; Argentina; 2018; 48-49
0327-9545
1667-5746
CONICET Digital
CONICET
url http://hdl.handle.net/11336/221665
identifier_str_mv Tamoxifen alters lysosomes of breast cancer cells by a mechanism independent of its anti-estrogenic activity; XXXVI Reunión Científica Anual de la Sociedad de Biología de Cuyo; Mendoza; Argentina; 2018; 48-49
0327-9545
1667-5746
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://sbcuyo.org.ar/wp-content/uploads/2019/08/Biocell-2018.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Tech Science Press
publisher.none.fl_str_mv Tech Science Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269899753259008
score 13.13397

Publicaciones similares